Short Interest in Immatics (NASDAQ:IMTXW) Drops By 12.5%

Immatics (NASDAQ:IMTXW) was the recipient of a significant drop in short interest during the month of March. As of March 31st, there was short interest totalling 1,400 shares, a drop of 12.5% from the March 15th total of 1,600 shares. Based on an average trading volume of 4,000 shares, the short-interest ratio is currently 0.4 days.

Immatics Price Performance

Shares of NASDAQ IMTXW opened at $2.70 on Tuesday. Immatics has a twelve month low of $1.39 and a twelve month high of $4.14. The firm has a fifty day simple moving average of $3.28 and a 200 day simple moving average of $2.96.

Hedge Funds Weigh In On Immatics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Aristeia Capital LLC lifted its holdings in Immatics by 3,293.6% in the fourth quarter. Aristeia Capital LLC now owns 754,590 shares of the company’s stock valued at $1,856,000 after buying an additional 732,354 shares during the period. JPMorgan Chase & Co. increased its stake in Immatics by 11.9% in the second quarter. JPMorgan Chase & Co. now owns 378,197 shares of the company’s stock valued at $1,293,000 after purchasing an additional 40,168 shares in the last quarter. Walleye Capital LLC increased its stake in Immatics by 25.7% in the second quarter. Walleye Capital LLC now owns 260,079 shares of the company’s stock valued at $889,000 after purchasing an additional 53,153 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in Immatics in the fourth quarter valued at $529,000. Finally, Jefferies Financial Group Inc. bought a new stake in Immatics in the fourth quarter valued at $80,000.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.